Bacillus Strain SOD Composition for Oxidative Stress in Fibrosis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for fibrotic diseases such as pulmonary fibrosis and hepatic fibrosis are inadequate, with no effective drugs available to address oxidative stress and fibrosis progression.

Innovation Solution

A composition comprising Bacillus sp. strains, their spores, or superoxide dismutase (SOD) is administered to prevent or treat fibrotic diseases by reducing reactive oxygen species and ameliorating fibrosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional drugs are used to treat fibrotic diseases, then treatment is provided, but no effective drugs are available to address oxidative stress and fibrosis progression

Engineering Contradiction:
Improveeffectiveness of treatmentVSAvoidability to address oxidative stress
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts and utilizes superoxide dismutase (SOD), a specific antioxidant enzyme, from Bacillus sp. strain to directly address oxidative stress in fibrotic diseases. This extraction of the key functional component (SOD) resolves the contradiction by providing a targeted therapeutic agent that specifically addresses oxidative stress, which conventional drugs fail to do.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The Bacillus sp. strain serves as a biological intermediary that produces and delivers superoxide dismutase to the affected tissues. This intermediary approach allows the treatment to effectively address oxidative stress while maintaining compatibility with the body's physiological systems, overcoming the limitations of conventional drugs.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If extracellular matrix accumulates in tissues causing fibrosis, then structural and functional problems occur, but the underlying cause may be unknown

Engineering Contradiction:
Improveextracellular matrix accumulationVSAvoidunknown etiology
Core Design Contradiction:
Object-affected harmful factorsVSLoss of information

Solution Approach 1:

The patent converts the harmful effect of oxidative stress (which contributes to ECM accumulation and fibrosis) into a beneficial therapeutic target. By administering superoxide dismutase to neutralize reactive oxygen species, the treatment transforms the harmful oxidative environment into a controlled therapeutic intervention, addressing both the harmful accumulation and the unknown etiology through mechanistic targeting.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Object-affected harmful factors

If reactive oxygen species concentration is high in fibrotic diseases, then oxidative stress increases, but effective treatment to reduce ROS is unavailable

Engineering Contradiction:
Improvereactive oxygen species concentrationVSAvoidavailability of effective treatment
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The Bacillus sp. strain performs self-service by producing and secreting superoxide dismutase as part of its metabolic function. This self-service capability of the bacterial strain provides a reliable and sustainable source of antioxidant enzyme treatment, resolving the contradiction by making effective ROS-reducing treatment naturally available through the biological system itself.

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively ameliorates fibrosis by reducing oxidative stress, improving disease indicators, and enhancing survival rates in animal models, particularly in pulmonary fibrosis and nonalcoholic steatohepatitis.

Implementation Method 1

a composition comprising a Bacillus sp. strain expressing superoxide dismutase, a Bacillus sp. strain spore, and/or a superoxide dismutase (SOD), and a use thereof for preventing, ameliorating, or treating a fibrotic disease

Methodology Applied
Scientific EffectSuperoxide dismutase catalysis: Enzyme

Data Source

PatentEP4595967A1Bacillus species strain expressing superoxide dismutase, bacillus species strain spore and/or superoxide dismutase, and use thereof for preventing or treating of fibrotic disease
Publication Date: 2025.08.06 HLB GENEX INC
  • EP4595967A1 patent drawingFigure 1
  • EP4595967A1 patent drawingFigure 2
  • EP4595967A1 patent drawingFigure 3A

AI summary

The present invention relates to a composition for the prevention, alleviation, or treatment of fibrotic diseases, containing a Bacillus species strain, a Bacillus species strain spore, each expressing superoxide dismutase, and/or superoxide dismutase. When orally administered, the composition allows the polypeptide with superoxide dismutase activity to remove reactive oxygen species in vivo, thus being helpful for the prevention, improvement, or treatment of fibrotic diseases such as pulmonary fibrosis or hepatic fibrosis.